Iron in Chronic Brain Disorders: Imaging and Neurotherapeutic Implications

Neurotherapeutics

Volumn 4, Issue 3, 2007, Pages 371-386

  Stankiewicz, James ^a   Panter, S Scott ^c   Neema, Mohit ^a   Arora, Ashish ^a   Batt, Courtney E ^a   Bakshi, Rohit ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; chelation; Iron; MRI; multiple sclerosis; neurodegeneration; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DEFEROXAMINE; IRON; RETINOL; UBIDECARENONE;

ALZHEIMER DISEASE; ARTICLE; BIOCHEMISTRY; BRAIN DISEASE; CHRONIC DISEASE; HISTOLOGY; HUMAN; IN VIVO STUDY; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PHYSIOLOGY; PRIORITY JOURNAL; TOPOGRAPHY;

ANIMALS; BRAIN; HUMANS; IRON; IRON METABOLISM DISORDERS; MAGNETIC RESONANCE IMAGING; NEURODEGENERATIVE DISEASES;

EID: 34250783638     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.05.006     Document Type: Article

References (182)

1. Gutteridge J.M. Iron and oxygen radicals in brain. Ann Neurol 32 (1992) S16-S21
2. Pujol J., Juque C., Vendrell P., et al. Biological significance of iron-related magnetic resonance imaging changes in the brain. Arch Neurol 49 (1992) 711-717
3. Wills A.J., Sawle G.V., Guilbert P.R., and Curtis A.R. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry 73 (2002) 91-92
4. Riederer P., Sofic E., Rausch W.D., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52 (1989) 515-520
5. Dexter D.T., Wells F.R., Agid F., et al. Increased nigral iron content in post-mortem parkinsonian brain. Lancet 341 (1987) 1219-1220
6. Berg D., and Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 21 (2006) 1299-1310
7. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 136 (1991) 6-15
8. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 suppl 3 (1996) S161-S170
9. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 899 (2000) 112-120
10. Youdim M.B., Ben-Shachar D., and Riederer P. Parkinson's disease and increased iron levels in substantia nigra zona compacta. Mov Disord 8 (1993) 1-12
11. House M.J., St Pierre T.G., Kowdley K.V., et al. Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer's disease patients. Magn Reson Med 57 (2007) 172-180
12. Loeffler D.A., Connor J.R., Juneau P.L., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 65 (1995) 710-716
13. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., and Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31 (1992) 327-335
14. Cornett C.R., Markesbery W.R., and Ehmann W.D. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19 (1998) 339-346
15. Dedman D.J., Treffry A., Candy J.M., et al. Iron and aluminum in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients. Biochem J 287 (1992) 509-514
16. Ehmann W.D., Markesbery W.R., Alauddin M., Hossain T.I., and Brubaker E.H. Brain trace elements in Alzheimer's disease. Neurotoxicology 7 (1986) 195-206
17. Honda K., Casadesus G., Petersen R.B., et al. Oxidative stress and redox-active iron in Alzheimer's disease. Ann NY Acad Sci 1012 (2004) 179-182
18. Drayer B., Burger P., Hurwitz B., et al. Reduced signal intensity on MR Images of thalamus and putamen in multiple sclerosis: increased iron content?. AJR Am J Roentgenol 149 (1987) 357-363
19. Bakshi R., Benedict R.H., Bermel R.A., et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59 (2002) 62-68
20. Craelius W., Migdal W.M., Lussenhop C.P., et al. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 106 (1982) 397-399
21. Inglese M., Ge Y., Jensen J., et al. Iron accumulation in the deep gray matter of patients with MS measured by magnetic field correlation. Neurology 64 suppl 1 (2005) A236
22. Brass S.D., Chen N.K., Mulkern R.V., and Bakshi R. Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17 (2006) 31-40
23. Ritchie C.W., Bush A.I., Mackinnon A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60 (2003) 1685-1691
24. Crapper McLachlan D.R., Dalton A.J., Kruck T.P., et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337 (1991) 1304-1308
25. Lynch S.G., Fonseca T., Levine S.M., et al. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cell Mol Biol 46 (2000) 865-869
26. Schenck J.F. Magnetic resonance imaging of brain iron. J Neurol Sci 207 (2003) 99-102
27. Haacke E.M., Cheng N.Y., House M.J., et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23 (2005) 1-25
28. Vymazal J., Brooks R.A., Baumgarner C., et al. The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med 35 (1996) 56-61
29. Chen J.C., Hardy P.A., Clauberg M., et al. T2 values in the human brain: comparison with quantitative assays of iron and ferritin. Radiology 173 (1989) 521-526
30. Bartzokis G., Sultzer D., Mintz J., et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psych 35 (1994) 480-487
31. Bartzokis G., Cummings J.L., Markham C.H., et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 17 (1999) 213-222
32. Bartzokis G., and Tishler T.A. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol Biol 46 (2000) 821-833
33. Gelman N., Gorell J.M., Barker P.B., et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 210 (1999) 759-767
34. Metafratzi Z., Argyropoulou M.I., Kiortsis D.N., et al. T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major. Br J Radiol 74 (2001) 407-410
35. Schenck J.F. Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths. J Neurol Sci 134 suppl (1995) 10-18
36. Vymazal J., Righini A., Brooks R.A., et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. Radiology 211 (1999) 489-495
37. Hardy P.A., Gash D., Yokel R., Andersen A., Ai Y., and Zhang Z. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging 21 (2005) 118-127
38. Graham J.M., Paley M.N., Grunewald R.A., Hoggard N., and Griffiths P.D. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 123 (2000) 2423-2431
39. Whittall K.P., MacKay A.L., Graeb D.A., et al. In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med 37 (1997) 34-43
40. Ordidge R.J., Gorell J.M., Deniau J.C., Knight R.A., and Helpern J.A. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 32 (1994) 335-341
41. Gorell J.M., Ordidge R.J., Brown G.G., et al. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45 (1995) 1138-1143
42. Antonini A., Leenders K.L., Meier D., et al. T2 relaxation time in patients with Parkinson disease. Neurology 43 (1993) 697-700
43. Bartzokis G., Aravagiri M., Oldendorf W.H., Mintz J., and Marder S.R. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med 29 (1993) 459-464
44. Reichenbach J.R., Venkatesan R., Yablonskiy D.A., et al. Theory and application of static field inhomogeneity effects in gradient-echo imaging. J Magn Reson Imaging 7 (1997) 266-279
45. Ma J., and Wehrli F. Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate. J Magn Reson Imaging 111 (1996) 61-69
46. Song R., and Song H.K. Echo-spacing optimization for the simultaneous measurement of reversible (R2') and irreversible (R2) transverse relaxation rates. Magn Reson Imaging 25 (2007) 63-68
47. Hikita T., Abea K., Sakodaa S., et al. Determination of transverse relaxation rate for estimating iron deposits in central nervous system. Neurosci Res 51 (2005) 67-71
48. Yablonskiy D., and Haacke M. An MRI method for measuring T2 in the presence of static and RF magnetic field inhomogeneities. Magn Reson Med 37 (1997) 872-876
49. Wheaton A.J., Borthakur A., Corbo M.T., et al. T2rho-weighted contrast in MR images of the human brain. Magn Reson Med 52 (2004) 1223-1227
50. Michaeli S., Oz G., Sorce D.J., et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 22 (2007) 334-340
51. Jensen J.H., Chandra R., Ramani A., et al. Magnetic field correlation imaging. Magn Reson Med 55 (2006) 1350-1361
52. Ponka P. Heredity causes of disturbed iron homeostasis in the central nervous system. Ann NY Acad Sci 1012 (2004) 267-281
53. Connor J.R., and Menzies S.L. Relationship of iron to oligodendrocytes and myelination. Glia 17 (1996) 83-93
54. Floris G., Meddad R., Padiglia A., and Musci G. The physiopathological significance of ceruloplasmin. Biochem Pharmacol 60 (2000) 1735-1741
55. Pantopoulos K. Iron metabolism and the IRE/IRP regulator system: an update. Ann NY Acad Sci (2004) 1012-1013
56. Ke Y., and Qian Z.M. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2 (2003) 246-253
57. Connor J.R., Boeshore S.A., Benkovic S.A., and Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37 (1994) 461-465
58. Levi S., Yewdall S.J., Harrison P.M., et al. Evidence that H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. J Biochem 288 (1992) 591-596
59. Zecca L., Stroppolo A., Gatti A., et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 101 (2004) 9843-9848
60. Zecca L., Zucca F.A., Albertini A., Rizzio E., and Fariello R.G. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 67 suppl 2 (2006) S8-S11
61. Moos T., and Morgan E.H. Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid. J Neurosci Res 54 (1998) 486-494
62. Curtis A.R., Fey C., Morris C.M., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28 (2001) 350-354
63. Schipper H.M. Heme oxygemase-1: transducer of pathological brain iron sequestration under oxidative stress. Ann NY Acad Sci 1012 (2004) 84-93
64. Fenton H.J.H. Oxidation of tartaric acid in presence of iron. J Chem Soc 65 (1894) 899-903
65. Liddell J.R., Hoepken H.H., Crack P.J., Robinson S.R., and Dringen R. Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity. J Neurosci Res 84 (2006) 578-586
66. Aguirre P., Mena N., Tapia V., et al. Antioxidant responses of cortex neurons to iron loading. Biol Res 39 (2006) 103-104
67. Crichton R.R., Wilmet S., Legssyer R., and Ward R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 91 (2002) 9-18
68. Van der Worp H.B., Thomas C.E., Kappelle L.J., et al. Inhibition of iron-dependent and ischemia-induced brain damage by the alpha-tocopherol analogue MDL74,722. Exp Neurol 155 (1999) 103-108
69. de Jesus Ferreira M.C., Crouzin N., Barbanel G., et al. A transient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action. Free Radic Biol Med 39 (2005) 1009-1020
70. Moos T. Brain iron homeostasis. Dan Med Bull 49 (2002) 279-301
71. Connor J.R., Menziew S.L., St. Martin S.M., and Mufson E.J. Cellular distribution of transferrin, ferritin and iron in normal and aged human brains. J Neurosci Res 27 (1990) 595-611
72. Zucca F.A., Bellei C., Giannelli S., et al. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J Neural Transm 113 (2006) 757-767
73. Zecca L., Youdim M.B.H., Riederer P., Conner J.R., and Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5 (2004) 863-873
74. Rouault T.A. Iron on the brain. Nat Genet 28 (2001) 299-300
75. Drayer B., Burger P., Darwin R., et al. MRI of brain iron. AJR Am J Roentgenol 147 (1986) 103-110
76. Hallgren B., and Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 3 (1958) 41-51
77. Thomas L.O., Boyko O.B., Anthony D.C., and Burger P.C. MR detection of brain iron. AJNR Am J Neuroradiol 14 (1993) 1043-1048
78. Milton W.H., Atlas S.W., Lexa F.J., Mozley P.D., and Gur R.E. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5T. Radiology 181 (1991) 715-719
79. Bartzokis G., Beckson M., Hance D.B., et al. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging 15 (1997) 29-35
80. Bartzokis G., Tishler T.A., Lu P.H., et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 28 (2007) 414-423
81. Cass W.A., Grondin R., Andersen A.H., et al. Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol Aging 28 (2007) 258-271
82. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann NY Acad Sci 1012 (2004) 326-341
83. Rottkamp C.A., Raina A.K., Zhu X., et al. Redox-active iron mediates amyloid-β toxicity. Free Radical Biol Med 30 (2001) 447-450
84. Mantyh P.W., Ghilardi J.R., Rogers S., et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61 (1993) 1171-1174
85. Bishop G.M., and Robinson S.R. β-Amyloid helps to protect neurons from oxidative stress. Neurobiol Aging 21 suppl 1 (2000) 226
86. Van Landeghem G., Sikstrom C., Beckman L., Adolfsson R., and Beckman R. Transferrin C2, metal binding and Alzheimer's disease. Neuroreport 9 (1998) 177-179
87. Pulliam J.F., Jennings C.D., Kryscio R.J., et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 119 (2003) 48-53
88. Bartzokis G., Sultzer D., Cummings J., et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57 (2000) 47-53
89. Bartzokis G., Tishler T.A., Shin I., Lu P.H., and Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann NY Acad Sci 1012 (2004) 224-236
90. House M.J., St Pierre T.G., Foster J.K., et al. Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss. AJNR Am J Neuroradiol 27 (2006) 430-439
91. Cherny R.A., Atwood C.S., Xilinas M.E., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30 (2001) 665-676
92. Uitti R.J., Rajput A.H., Rozdilsky B., et al. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 16 (1989) 310-314
93. Galazka-Friedman J., Bauminger E.R., Friedman A., et al. Iron in parkinsonian and control substantia nigra: a Mossbauer spectroscopy study. Mov Disord 11 (1996) 8-16
94. Youdim M.B., Ben Shachar D., and Riedere P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration. Acta Neurol Scand 126 suppl (1989) 47-54
95. Levenson C.W. Iron and Parkinson's disease: Chelators to the rescue?. Nutr Rev 61 (2003) 311-313
96. Andersen J.K. Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease?. Novartis Found Symp 235 (2001) 11-20
97. Dexter D.T., Carayon A., Vidailhet M., et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55 (1990) 16-20
98. Zecca L., Berg D., Arzberger T., et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 20 (2005) 1278-1285
99. Atasoy H.T., Nuyan O., Tunc T., et al. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores. Neurology India 52 (2004) 332-337
100. Kosta P., Argyropoulou M.I., Markoula S., et al. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 253 (2006) 26-32
101. Gerlach M., Double K.L., Youdim M.B., and Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 70 (2006) 133-142
102. Shoham S., and Youdim M.B. Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration. Ann NY Acad Sci 1012 (2004) 94-114
103. Ben-Shachar D., Eshel G., Finberg J.P., and Youdim M.B. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56 (1991) 1441-1444
104. Lan J., and Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104 (1997) 469-481
105. Kaur D., Yantiri F., Rajagopalan S., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 27 (2003) 899-909
106. Bakshi R., Shaikh Z.A., and Janardhan V. MRI T2 shortening ("black T2") in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 11 (2000) 15-21
107. Tjoa C.W., Benedict R.H., Weinstock-Guttman B., Fabiano A.J., and Bakshi R. MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis. J Neurol Sci 234 (2005) 17-24
108. Neema M., Stankiewicz J., Arora A., et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 17 suppl 1 (2007) 16-21
109. LeVine S.M. Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res 760 (1997) 298-303
110. Mehindate K., Sahlas D.J., Frankel D., et al. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J Neurochem 77 (2001) 1386-1395
111. Chakrabarty M.R., Emerson R., and Levine S.M. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Multiple Sclerosis 9 (2003) 372-381
112. Forge J.K., Pedchenko T.V., and LeVine S.M. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci 63 (1998) 2271-2284
113. Bakshi R., Shaikh Z.A., and Janardhan V. MRI T2 shortening ("black T2") in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 11 (2000) 15-21
114. Brass S.D., Benedict R.H., Weinstock-Guttman B., Munschauer F., and Bakshi R. Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 12 (2006) 437-444
115. Bermel R.A., Puli S.R., Rudick R.A., et al. Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 62 (2005) 1371-1376
116. Zhang Y., Zabad R.K., Wei X., Metz L.M., Hill M.D., and Mitchell J.R. Deep gray matter "black T2" on 3 tesla magnetic resonance image correlates with disability in multiple sclerosis. Mult Scler (2007) April 27, [E-pub ahead of print]
117. Bowern N., Ramshaw I., Clark I., and Doherty P. Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 160 (1984) 1532-1543
118. Willenborg D.O., Bowern N.A., Danta G., and Doherty P.C. Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen. J Neuroimmunol 17 (1988) 127-135
119. Pedchenko T.V., and LeVine S.M. Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice. J Neuroimmunol 84 (1998) 188-197
120. Weilbach F.X., Chan A., Toyka K.V., et al. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 135 (2004) 49-55
121. Pai V.B., and Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 4 (2000) 263-302
122. Mancuso M., Davidzon G., Kurlan R.M., et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 64 (2005) 280-294
123. Chinnery P.F., Crompton D.E., Birchall D., et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 130 (2007) 110-119
124. Duby G., Foury F., Ramazzotti A., Herrmann J., and Lutz T. A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum Mol Genet 11 (2002) 2635-2643
125. Waldvogel D., van Gelderen P., and Hallet M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 46 (1999) 123-125
126. Hart P.E., Lodi R., Rajagopalan B., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62 (2005) 621-626
127. Hayflick S.J., Hartman M., Coryell J., Gitschier J., and Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 27 (2006) 1230-1233
128. Zhou B., Westaway S.K., Levinson B., et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28 (2001) 345-349
129. Hayflick S.J. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 15 (2003) 572-577
130. Xu X., Pin S., Gathinji M., Fuchs R., and Harris Z.L. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci 1012 (2004) 299-305
131. Kawanami T., Kato T., Daimon M., et al. Hereditary caeruloplasmin deficiency: clinicopathological study of a patient. J Neurol Neurosurg Psychiatry 61 (1996) 506-509
132. Grisoli M., Piperno A., Chiapparini L., Mariani R., and Savoiardo M. MR imaging of cerebral cortical involvement in aceruloplasminemia. AJNR Am J Neuroradiol 26 (2005) 657-661
133. Harris Z.L., Durley A.P., Man T.K., and Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 96 (1999) 10812-10817
134. Vassiliev V., Harris Z.L., and Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Brain Res Rev 49 (2005) 633-640
135. Miyajima H., Takahaski Y., Kamata T., et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41 (1997) 404-407
136. Loreal O., Turlin B., Pigeon C., et al. Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights. J Hepatol 36 (2002) 851-856
137. Kuhn J., Bewermeyer H., Miyajima H., et al. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev 7 (2007) 450-453
138. Levy M., Turtzo C., and Llinas R.H. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol 3 (2007) 54-58
139. Koeppen A.H., Dickson A.C., Chu R.C., and Thach R.E. The pathogenesis of superficial siderosis of the central nervous system. Ann Neurol 34 (1993) 646-653
140. Unger E., Alexander A., Fritz T., Rosenberg N., and Dreisbach J. Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted images. Radiology 193 (1994) 473-476
141. Kamran S., and Bakshi R. MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images. Neuroradiology 40 (1998) 519-521
142. Nielsen J.E., Neerup Jensen L., and Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry 59 (1995) 318-321
143. Berg D., Hoggenmuller U., Hofmann E., et al. The basal ganglia in haemochromatosis. Neuroradiology 42 (2000) 9-13
144. Savoiardo M. Differential diagnosis of Parkinson's disease and atypical parkinsonian disorder by magnetic resonance imaging. Neurol Sci 24 suppl 1 (2003) S35-S37
145. Block S., and Bakshi R. FLAIR MRI of striatonigral degeneration. Neurology 56 (2001) 1200
146. Hauser R.A., Murtaugh F.R., Akhter K., et al. Magnetic resonance imaging of corticobasal degeneration. J Neuroimaging 6 (1996) 222-226
147. Dietrich R.B., and Bradley Jr. W.G. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. Radiology 168 (1988) 203-206
148. Hall E.D. Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol 32 (1992) S137-S142
149. Feng Y., LeBlanc M., LeBlanc E., et al. Desmethyl tirilazad improves neurologic function after hypoxic-ischemic brain injury in piglets. Crit Care Med 28 (2000) 1431-1438
150. Soloniuk D., Perkins E., and Wilson J. Use of allopurinol and deferoxamine in cellular protection during ischemia. Surg Neurol 38 (1992) 110-113
151. Rosenthal E., Chanderbhan R., Marshall G., and Fiskum G. Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine. Free Radic Biol Med 12 (1992) 29-33
152. RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke 27 (1996) 1453-1458
153. Haley Jr. E.C. High-dose tirilazad for acute stroke (RANTTAS II). Stroke 29 (1998) 1256-1257
154. Balla G., Vercellotti G.M., Muller-Eberhard U., Eaton J., and Jacob H.S. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest 64 (1991) 648-655
155. Long D.A., Ghosh K., Moore A.N., Dixon C.E., and Dash P.K. Deferoxamine improves spatial memory performance following experimental brain injury in rats. Brain Res 717 (1996) 109-117
156. Panter S.S., Baughler J.M., and Hall E.D. Dextran-coupled deferoxamine improves outcome in a murine model of head injury. J Neurotrauma 9 (1992) 47-53
157. Marshall L.F., Maas A.I., Marshall S.B., et al. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury. J Neurosurg 89 (1998) 519-525
158. Qian M., and Eaton J.W. Glycochelates and the etiology of diabetic peripheral neuropathy. Free Radic Biol Med 28 (2000) 652-656
159. Cameron N.E., and Cotter M.A. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96 (1995) 1159-1163
160. Cameron N.E., and Cotter M.A. Effects of an extracellular metal chelator on neurovascular function in diabetic rats. Diabetologia 44 (2001) 621-628
161. Fernandez-Real J.M., Penarroja G., Castro A., Garcia-Bragado F., Lopez-Bermejo A., and Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 25 (2002) 2249-2255
162. Duffy S.J., Biegelsen E.S., Holbrook M., et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103 (2001) 2799-2804
163. Buyse G., Mertens L., Di Salvo G., et al. Idebenone treatment in Friedreich's ataxia. Neurology 60 (2003) 1679-1681
164. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., and Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21 (2001) 4183-4187
165. Petersen R.C., Thomas R.G., Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
166. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336 (1997) 1216-1222
167. Levites Y., Weinreb O., Maor G., Youdim M.B., and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78 (2001) 1073-1082
168. Fahn S., and Cohen G. The oxidant stress hypothesis in idiopathic Parkinson's: evidence supporting it. Ann Neurol 32 (1992) 799-803
169. Singh N., Pillay V., and Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog Neurobiol 81 (2007) 29-44
170. Lehmann D., Karussis D., Misrachi-Koll R., et al. Oral administration of the oxidant scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol 50 (1994) 35-42
171. Ruuls S.R., Bauer J., Sontrop K., et al. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56 (1995) 207-217
172. Hansen L.A., Willenborg D.O., and Cowden W.B. Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the antioxidant, butylated hydroxyanisole. J Neuroimmunol 62 (1995) 69-77
173. Malfroy B., Doctrow S.R., Orr P.L., Tocco G., Fedoseyeva E.V., and Benichou G. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 177 (1997) 62-68
174. Marracci G.H., Jones R.E., McKeon G.P., et al. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 13 (2002) 104-114
175. Aktas O., Prozorovski T., Smorodchenko A., et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173 (2004) 5794-5800
176. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007) 842-857
177. Lee J.Y., Friedman J.E., Angel I., Kozak A., and Koh J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human b-amyloid precursor protein transgenic mice. Neurobiol Aging 25 (2004) 1315-1321
178. Shin R.W., Kruck T.P., Murayama H., and Kitamoto T. A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer's disease. Brain Res 961 (2003) 139-146
179. Gaeta A., and Hider R.C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146 (2005) 1041-1059
180. Ben-Shachar D., Kahana N., Kampel V., Warshawsky A., and Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46 (2004) 254-263
181. Gal S., Zheng H., Fridkin M., and Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95 (2005) 79-88
182. Liu G., Men P., Harris P.L., et al. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett 406 (2006) 189-193